This webinar summary from the IQVIA Institute reviews the current state of CAR-T cell therapy development and adoption. It covers advances in efficacy, expanding indications, and earlier-line use, alongside persistent challenges such as manufacturing complexity, cost, access limitations, and patient identification. The brief highlights trends in global pipeline growth, competitive dynamics, and health system readiness. IQVIA emphasizes the importance of coordinated ecosystem planning, real-world evidence, and policy innovation to support broader, more equitable access to CAR-T therapies.

Join for free to read